Cam Penner fitted a helmet on Doug at June's annual Ride for Doug fundraising ride.

UPDATED: Langley dad disappointed bid for medication approval denied

The FDA chose to not approve a drug that, according to Cam Penner, makes a huge difference in his son Doug’s life.

Langley’s Cam Penner efforts to help his 13-year-old son Doug, and others with Duchenne muscular dystrophy (DMD), hit a major road block this week.

According to Muscular Dystrophy Canada, DMD is an inherited disorder. The muscles become weaker as the patient gets older.

Doug is also the face behind Ride for Doug, an annual fundraiser organized by Cam.

On Nov. 24, Cam flew to Washington DC, where he addressed the Food and Drug Administration Advisory Committee about the impact that Drisapersen makes on Doug’s daily living.

“The study we have been on since 2011 has finally reached the stage where the FDA needs to either approve or reject it,” Cam explained in mid-December, as he awaited the ruling.

“If approved, other boys with DMD will be able to access the same medication Doug has been taking.”

On Thursday, Cam informed the Langley Advance that the FDA ruled not approve the drug at this time.

“No reasons for this decision have been released,” Cam said.

The drug company BioMarin has issued a press release that current studies will continue for now.

This means Doug will still get his Drisapersen.

“Thank you BioMarin,” Cam said.

According to BioMarin, Duchenne affects approximately one in every 3,500 to 5,000 male children, making it the most common fatal genetic disorder diagnosed in childhood.

There is currently no FDA-approved therapy designed specifically to treat Duchenne.

For now, Cam said, he and others supporting the use of the drug do not know what is happening next.

“Drisapersen is under review by the EU equivalent of the FDA,” Cam said. “There is no timeline on if or when Canada will be included.”

While extremely disappointing for the Duchenne community, Cam said “our Medical Explorer will continue with his weekly treatments while we watch and pray that we continue to see its benefits.”

Prior to the ruling, Cam said a rejection “may spell the end to Drisapersen, and leave DMD boys with exactly zero approved treatments.”

As with all experimental medications, there have been risks, side effects, and confusing data, Cam explained.

“The FDA is wading through all of these issues and deliberating whether or not to allow access to this drug,” he said last month. “At this point in time, there are no other approved treatments for DMD. None.”

To view the BioMarin press release, click here.

Just Posted

VIDEO: Giants winning streak halts against Everett Friday at home in Langley

Following their first loss since November, G-Men hope to regroup and defeat Victoria on Saturday.

Two local squads meet up at senior girls tourney in Langley

The 2018 Girls Tsumura Invitational continues Saturday with the finals.

Cloverdale’s annual winter ice palace to open Dec. 21

Cloverdale Arena’s 21st-annual ice palace will open on Dec. 21

Langley Advance What’s On: Dec. 13, 2018 edition

Submit Langley events: LangleyAdvance.com/add-event or news@langleyadvance.com (subject: What’s On).

Langley Advance Christmas Fun: Dec. 13, 2018 edition

Send details to LangleyAdvance.com/add-event or news@langleyadvance.com, subject“Christmas fun.”

VIDEO: Royals reveal the images on their Christmas cards

Prince William and his wife Kate are shown outside in casual clothes, their three young children in tow

ICBC to apply for 6.3% hike to basic insurance rates

Crown Corporation said it will be submitting its next basic rate application to the British Columbia Utilities Commission Friday

Media, robotics, Indigenous studies coming to B.C. Grade 12 classrooms in 2019-20

Provincial tests are also being changed for students in Grade 10 to 12, the Education Ministry said

Stranded B.C. trucker writes final wishes before being rescued 3 days later

‘I was just praying someone would come along’

Canfor Corp. extending temporary curtailment of sawmills in B.C.; cutting hours

Vancouver-based company says the decision is due to declining lumber prices, high log costs and log supply constraints

Canada’s prospective world junior team members await final roster decisions

Thirty-four players were invited to the national junior selection camp

Family searching for B.C. professor last seen at Colombian salsa club

Ramazan Gencay, a professor in economics at Simon Fraser University, was last seen in Medellin

Rash of bomb threats a learning opportunity for response capacity, Goodale

Thursday’s wave of bomb threats swept across communities on both sides of the Canada-U.S. border

Swap food for fines at Fraser Valley Regional Library

From Dec. 14 through Jan. 22, library patrons can “pay” their fines while helping local food banks

Most Read